Clinical trial
Thalidomide in Mucosa Associated Lymphoid Tissue (MALT) Lymphoma Patients
NCT00373646 · Medical University of Vienna, Other · Completed
Key facts
| NCT number | NCT00373646 |
|---|---|
| Title | Thalidomide in Mucosa Associated Lymphoid Tissue (MALT) Lymphoma Patients |
| Official title | Phase II Trial of Thalidomide (Thalidomide Pharmion) in Patients With Advanced or Relapsed Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT) |
| Lead sponsor | Medical University of Vienna, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | MALT Lymphoma |
| Intervention type | Drug |
| Interventions | Thalidomide, Pharmion |
| Enrollment | 8 |
| Start date | Jun 1, 2006 |
| Primary completion | Jan 1, 2009 |
| Completion | Jan 1, 2009 |
| First posted | Sep 8, 2006 |
| Last update posted | Jun 18, 2009 |
| Countries | Austria |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: